{"preliminary_commentary":{"by_channel":{"x_thread":144,"youtube":64,"podcast":50,"bluesky_thread":16,"x_video":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04025879\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T05:17:53.017Z","note":"Automated from the 40 newest of 276 indexed sources (Jul 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether adjuvant nivolumab adds benefit beyond neoadjuvant treatment\n- Whether ctDNA can guide postoperative immunotherapy decisions\n- How to manage patients without a pathologic complete response"},"name":"CheckMate 77T","nct_id":"NCT04025879","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-77t-nct04025879. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Neoadj. Nivo+ Pt-based Doublet Chemo followed by Adj. Nivo","type":"EXPERIMENTAL"},{"description":null,"label":"Neoadj. Plac. + Pt-based Doublet Chemo followed by Adj.Plac.","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":461,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":["Opdivo, BMS936558"],"type":"BIOLOGICAL"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-26","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-07-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-Free Survival (EFS) by BICR","timeFrame":"From randomization to disease progression, worsening, recurrence, or death due to any cause (up to approximately 44 months)"}],"references":[{"citation":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Tanaka F, Cornelissen R, Petruzelka LB, Gao Y, Pujol JL, Ito H, de Oliveira Muniz Koch L, Ciuleanu TE, Wu L, Bohnet S, Watanabe Y, Taube JM, Deutsch JS, Erdmann CC, Meadows-Shropshire S, Neely J, Ip V, Hung YH, Sathyanarayana P, Bhatia S, Chu K, Blum SI, Lucherini S, Eddy N, Yadav A, Provencio M. Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. Nature. 2026 Aug 12. doi: 10.1038/s41586-026-10925-6. Online ahead of print.","pmid":"42587156","type":"DERIVED"},{"citation":"Provencio M, Awad MM, Spicer JD, Janssens A, Moiseyenko F, Gao Y, Watanabe Y, Alexandru A, Guisier F, Frost N, Franke F, Hiltermann TJN, He J, Tanaka F, Lu S, Coronado Erdmann C, Sathyanarayana P, Tran P, Devas V, Cascone T. Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis. Nat Cancer. 2026 Jan;7(1):169-181. doi: 10.1038/s43018-025-01104-z. Epub 2026 Jan 8.","pmid":"41507539","type":"DERIVED"},{"citation":"Tanaka F, Watanabe Y, Sugawara S, Okami J, Muto S, Okada M, Horio Y, Tsuboi M, Sato Y, Takamochi K, Horinouchi H, Tambo Y, Seike M, Okishio K, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Ito H. Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T. Cancer Sci. 2026 Mar;117(3):759-768. doi: 10.1111/cas.70300. Epub 2025 Dec 23.","pmid":"41431434","type":"DERIVED"},{"citation":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926.","pmid":"38749033","type":"DERIVED"},{"citation":"Leal TA, Ramalingam SS. Neoadjuvant therapy gains FDA approval in non-small cell lung cancer. Cell Rep Med. 2022 Jul 19;3(7):100691. doi: 10.1016/j.xcrm.2022.100691.","pmid":"35858590","type":"DERIVED"},{"citation":"Hong WX, Sagiv-Barfi I, Czerwinski DK, Sallets A, Levy R. Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. Cancer Res. 2022 Apr 1;82(7):1396-1408. doi: 10.1158/0008-5472.CAN-21-1382.","pmid":"35135810","type":"DERIVED"}],"start_date":{"date":"2019-11-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04025879"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-77t-nct04025879"}